Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics

British Journal of Psychiatry

Volumn 174, Issue MAY SUPPL. 38, 1999, Pages 34-43

  Barnes, Thomas R E ^a   McPhillips, Mike A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; SERTINDOLE;

AGRANULOCYTOSIS; AKATHISIA; CLINICAL TRIAL; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; MOTOR DYSFUNCTION; NEUROLEPTIC MALIGNANT SYNDROME; NONHUMAN; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PARKINSONISM; QT INTERVAL; REVIEW; SEIZURE; SEXUAL DYSFUNCTION; TACHYCARDIA; TARDIVE DYSKINESIA; URINE INCONTINENCE; WEIGHT GAIN; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG EFFECT; ELECTROCARDIOGRAPHY; EXTRAPYRAMIDAL SYNDROME; FEMALE; LIVER; MALE; PSYCHOSEXUAL DISORDER; QUALITY OF LIFE;

AGRANULOCYTOSIS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; LIVER; MALE; QUALITY OF LIFE; SEIZURES; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; URINARY INCONTINENCE; WEIGHT GAIN;

EID: 0032893560     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/s0007125000298097     Document Type: Review

References (94)

1. Aizenberg, D., Zemishlany, Z., Dorfman-Etrog, P., et al (1995) Sexual dysfunction in male schizophrenic patients. Journal of Clinical Psychiatry, 56, 137-141.
2. Alvir, J. M. J., Lieberman, J. A., Safferman, A. Z., et of (1993) Clozapine-induced agranulocytosis: Incidence and risk factors in the United States. New England Journal of Medicine, 329, 162-167.
3. Anon (1993) Risperidone and remoxipride for schizophrenia. Drug and Therapeutics Bulletin, 31, 101-102.
4. (1997) Olanzapine, sertindole and schizophrenia. Drug and Therapeutics Bulletin, 35, 81-83.
5. Arvanitis, L. A., Miller, B. G. & the Seroquel Trial 13 Study Group (1997) Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biological Psychiatry, 42, 233-246.
6. Atkin, K., Kendall, F., Gould, D., et al (1996) Neutropenia and agranulocytosis in patients receiving ciozapine in the UK and Ireland. British Journal of Psychiatry, 169, 483-488.
7. Aunsholt, N. A. (1989) Prolonged QT interval and hypokalaemia caused by haloperidol. Acta Psychiatrica Scandinavica, 79, 411-412.
8. Awad, A. G. & Hogan, T. P. (1994) Subjective response to neuroleptics and quality of life-implications for treatment outcome. Acta Psychiatrica Scandinavica, 89 (suppl. 380), 27-32.
9. Barnes, T. R. E. (1989) A rating scale for drug-induced akathisia. British Journal of Psychiatry, 154, 672-676.
10. _ (1992) Neuromuscular effects of neuroleptics: Akathisia. In Adverse Effects of Psychotropic Drugs (eds J. M. Kane & J. A. Lieberman), pp. 201-217, New York: Guilford Press.
11. _ & Guy Edwards, J. (1993) The side-effects of antipsychotic drugs. I. CNS and neuromuscular effects. In Antipsychotic Drugs and Their Side Effects (ed. T. R. E. Barnes), pp. 213-247. London: Academic Press.
12. _ & Harvey, C. A. (1993) Psychiatric drugs and sexuality. In Sexual Pharmacology (eds A. J. Riley, M. Peet. & C. Wilson), pp. 176-196. Oxford: Oxford Medical Publications.
13. _ & McPhillips, M. A. (1995) How to distinguish between the neuroleptic induced deficit syndrome, depression and disease-related negative symptoms in schizophrenia. International Clinical Psychopharmacology, 10, 115-121.
14. _ & _ (1996) Antipsychotic induced extrapyramidal symptoms: Role of anticholinergic drugs in treatment. CNS Drugs, 6, 315-330.
15. Beasley, C. M. (1997) Safety of olanzapine. Journal of Clinical Psychiatry, 15, 19-21.
16. _ , Sanger, T., Satterlee, W., et al (1996a) Olanzapine versus placebo: acute phase results of a double-blind, fixed dose olanzapine trial. Psychopharmacology, 124, 159-167.
17. _ , Tollefson, G., Tran, P., et al (1996b) Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology, 14, 111-123.
18. Bhavnani, S, M. & Levin, G. M. (1996) Antipsychotic agents: a survey of the prevalence, severity and burden of side effects. International Clinical Psychopharmacology, II, 1-12.
19. Bollen, C. A., De Cuyper, C. H., Eneman, H., et al (1992) Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatrica Scandinavica, 85, 295-305.
20. Boyer, P., Lecrubier, Y., Peuch, A. J., et al (1995) treatment of negative symptoms in schizophrenia with amisulpride. British Journal of Psychiatry, 166, 68-72.
21. Brecher, M. (1996) Long-term safety of risperidone (abstract P 15-1). European Neuropsychopharmacology, 6 (suppl. 3), 170.
22. Casey, D. E. (1996) Side effect profiles of new antipsychotic agents. Journal of Clinical Psychiatry, 57 (suppl. 11), 40-45.
23. _ , (1997) The relationship of pharmacology to side effects. Journal of Clinical Psychiatry, 58 (suppl. 10), 55-62.
24. Ceskova, E. & Svetska, J. (1996) Efficacy and tolerance of risperidone in various doses. Ceska a Slovenska Psychiatric, 92, 50-56.
25. Chengappa, K. N., Shelton, M. D., Baker, R. W., et al (1994) The prevalence of akathisia in patients receiving stable doses of clozapine. Journal of Clinical Psychiatry, 55, 142-145.
26. Chouinard, G. (1990) A placebo - controlled clinical trial of remoxipride and chlorpromazine in newly-admitted schizophrenic patients with acute exacerbation. Acta Psychiatrica Scandinavica, 82 (suppl. 358), 111-119.
27. _ , Ross-Choulnard, A., Annable, L., et al (1980) the extrapyramidal symptom rating scale. Canadian Journal of Neurological Science, 7, 233.
28. _ , Jones, B., Remington, G., et al (1993) A Canadian multi center placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology, 13, 25-40.
29. Claghorn, J., Honigfeld, G., Abuzzahab, F. S., et al (1987) The risks and benefits of clozapine versus chlorpromazine. Journal of Clinical Psychopharmacology, 7, 377-384.
30. Claus, A., Bollen, J., Cuyperf H., et al (1992) Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double blind comparative study. Acta Psychiatrica Scandinavica, 85, 295-305.
31. Cohen, B. M., Keck, P. E., Satlin, A., et al (1991) Prevalence and severity of akathisia in patients on clozapine. Biological Psychiatry, 29, 1215-1219.
32. Coukell, A. J., Spencer, C. M. & Benfield, P. (1996) Amisulpride: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs, 6, 237-256.
33. Daniel, D., Goldberg, T. E., Weinberger, D. R., et al (1996) Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: A pilot study. American Journal of Psychiatry, 153, 417-419.
34. Devinsky, O. & Pacia, S. V. (1994) Seizures during clozapine therapy. Journal of Clinical Psychiatry, 55(B): 153-156.
35. Factor, S. A. & Friedman, J. H. (1997) The emerging role of clozapine in the treatment of movement disorders. Movement Disorders, 12, 483-496.
36. Fleischhacker, W.W., Meise, U., Gunther, V., et al (1994) Compliance with antipsychotic drug treatment: influence of side-effects. Acta Psychiatrica Scandinavica, 89 (suppl. 382), 11-15.
37. Franz, M., Lis, S., Pluddemann, K., et al (1997) Conventional versus atypical antipsychotics: subjective quality of life In schizophrenic patients. British Journal of Psychiatry, 170, 422-425.
38. Freeman, H. L. (1997) Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia. International Clinical Psychopharmacology, 12(suppl. 2), 11-17.
39. Fuller, M. A., Borovicka, M. C., Jaskiw, G. E., et al (1996) Clozapine-induced urinary incontinence: incidence and treatment with ephedrine. Journal of Clinical Psychiatry, 57, 514-518.
40. Gerlach, J. & Peacock, L. (1995) Intolerance to neuroteptic drugs: the art of avoiding extrapyramidal syndromes. European Psychiatry, 10 (suppl. 1), 27-31.
41. Grohmann, R., Schmidt, L. G., Speiss-Kiefer, C., et al (1989) Agranulocytosis and significant leucopenia with neuroleptic drugs: results from the AMUP program. Psychopharmacology, 99 (suppl.), 109-112.
42. Guy Edwards, J. & Barnes, T. R. E. (1993) The side-effects of antipsychotic drugs II. Effects on other physiological systems. In Antipsychotic Drugs and Their Side-Effects (ed. T. R. E. Barnes), pp. 249-275. London Academic Press.
43. Hale, A. S. (1998) A review of the safety and tolerability of sertindole. International Clinical Psychopharmacology, 13 (suppl. 3), 65-70.
44. Halstead, S. M., Barnes, T. R. E. & Speller, J. C. (1994) Akathisia: prevalence and associated dysphoria in an in-patient population with chronic schizophrenia. British Journal of Psychiatry, 164, 177-183.
45. Heimberg, C., Gallacher, F., Gur, R. C., et al (1995) Diet and gender moderate clozapine related weight gain. Human Psychopharmacology, 10, 367-71.
46. Jensen, V. E. & Gotzsche, O. (1994) Allergic myocarditis in clozapine treatment. Ugeskrift for Laeger (Copenhagen), 156, 4151-4152.
47. Josefson, D. (1997) Hay fever drug to be banned by the FDA. British Medical Journal, 314, 248.
48. Jurivich, D. A., Hanlon, J. & Andolsek, K. (1987) Neuroleptic-induced neutropenia in the elderly. Journal of the American Geriatrics Society, 35, 248-250.
49. Kane, J. M. (1994) Risperidone (editorial). American Journal of Psychiatry, 151, 802-803.
50. _ , Honigfeld, G., Singer, J., et al (1988) Clozapine for the treatment-resistant schizophrenic. Archives of General Psychiatry, 45, 789-796.
51. Kerwin, R. W. (1994) The new atypical antipsychotics: a lack of extrapyramidal side-effects and new routes in schizophrenia research. British Journal of Psychiatry, 164, 141-148.
52. Klieser, E., Lehmann, E., Kinzler, E., et al (1995) Randomised, double blind controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. Journal of Clinical Psychopharmacology, 15 (suppl. 1), 45-51.
53. Krahenbuhl, S., Sauter, B., Kupferschmidt, H., et al (1995) Case report: reversible QT prolongation with torsade de pointes in a patient with pimozide intoxication. American Journal of Medical Science, 309, 315-316.
54. Kuchenhoff, B. (1993) Die wichtigsten Nebenwirkungen unter Clozapin (Leponex) und ihre Behandlung. Psychiatrische Praxis, 20, 201-206.
55. Kurz, M., Hummer, M., Oberhauer, H., et al (1995) Extrapyramidal side-effects of clozapine and haloperidol. Psychopharmacology, 118, 52-56.
56. Lader, M. H. (1993) Neuroleptic induced deficit syndrome: old problem, new challenge. Journal of Psychopharmacology, 7, 392-393.
57. Lamberti, J. S., Bellnier, T. & Schwarzkopf, S. B. (1992) Weight gain among schizophrenic patients treated with clozapine. American Journal of Psychiatry, 149, 689-690.
58. _ & _ (1993) Clozapine and tardive dyskinesia. Journal of Nervous and Mental Disease, 181, 137-138.
59. Lande, G., Drouin, E., Gauthier, C., et al (1992) Effets arythmogènes du chlorydrate de sultopride: correlation clinique et electrophysiologique cellulaire. Annales Françaises d'Anesthésie et de Réanimation, 11, 629-635.
60. Lewander, T., Westerbergh, S.-E. & Morrison, D. (1990) Clinical profile of remoxipride a combined analysis of a comparative double-blind multicentre trial programme. Acta Psychiatrica Scandinavica, 82, 92-98.
61. Lilleng, P., Morild, I. & Hope, M. (1995) Clozapine and myocarditis. Tidsskrift for den Norske Laegeforening, 115, 3026-3027.
62. Linzasoro, G., Marti-Masso, J. F. & Suarez, J. A. (1993) Nocturnal akathisia in Parkinson's disease: treatment with clozapine. Movement Disorders, 8, 1/1 174.
63. Lingjaerde, O., Ahlfors, U., Bech, P., et al (1987) The UKU Side Effect Rating Scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side-effects in neuroleptic treated patients. Acta Psychiatrica Scandinavica, 76, 1-100.
64. Loo, H., Polrier-Littré, M-F., Thėron, M., et al (1997) Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. British Journal of Psychiatry, 170, 18-22.
65. Marder, S. R. & Meibach, R. C. (1994) Risperidone in the treatment of schizophrenia. American Journal of Psychiatry, 151, 825-835.
66. Mekker, J. E., Herrmann, P. W., Som, C. W., et al (1991) Clozapine tissue concentrations following an apparent suicidal overdose of Cozaril. Journal of Analytical loxology, 16, 54-56.
67. Merschel, A., Oberlé, J. & Rangoni, F. (1993) La clozapine. effets indêsirables: Etude dans les CHS de la région Alsace. Pharmacie Hospitalière française, 106, 231-242.
68. Moller, H.-J.(1996) Extrapyramidal side-effects of neuroleptic medication: Focus on risperidone. In Seratonin in Antipsychotic Treatment: Mechanisms and Clinical Practice (eds J. M. Kane, H-J. Moller & F. Awouters), pp. 345-356. New York: Marcel Dekker.
69. Monteiro, W. O., Noshirvani, H. F., Marks, I. M., et al (1987) Anorgasmia from clomipramine in obsessive compulsive disorder: a controlled trial. British Journal of Psychiatry, 151, 107-112.
70. Mortimer, A. & Barnes, T. R. E. (1996) The treatment of schizophrenia: Comparative studies with placebo, haloperidol and risperidone. In Serotonergic Mechanisms in Antipsychotic Treatment (eds J. M. Kane, H-J. Moller & R. Awouters), pp. 311-330. New York: Marcel Dekker.
71. Owens, D. G. C. (1996) Adverse effects of antipsychotic agents: Do newer agents offer advantages? Drugs, 51, 895-930.
72. Peuskens, J. (1995) Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Biritish Journal of Psychiatry, 166, 712-726.
73. Pisciotta, A. V. (1978) Drug-induced agranulocytosis. Drugs, 15, 132-143.
74. Pollack, M. H., Reiter, S. & Hammerness, P. (1992) Genitourinary and sexual adverse effects of psythotropic medication. International Journal of Psychiatry in Medicine, 22, 305-327.
75. Ramirez, L., Silber, C. & Mack, R. (1997) The long-term cardiovascular safety of sertindole (abstract). Schizophrenia Research, 24, 202.
76. Royal College of Psychiatrists (1997) The Association Between Antipsychotic Drugs and Sudden Death. Council Report CR5/. London: Royal College of Psychiatrists.
77. Safferman, A. Z., Lieberman, J. A., Pollack, S., et al (1993) Akathisia and clozapine treatment. Schizophrenia Research, 9, 248-249.
78. Simpson, G. M. & Angus, J . W. S. (1970) A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica Supplementum, 212, 1-19.
79. Small, J. G., Hirsch, S. R., Arvanitis, L. A., et al, and the Seroquel Study Group (1997) Quetiapine in patients with schizophrenia. Archives of General Psychiatry, 54, 549-557.
80. Song, F. (1997) Risperidone in the treatment of schizophrenia: a meta-anatysis of randomized, controlled trials, Journal of Psychopharmacology, 11, 65-71.
81. Speller, J. C., Barnes, T. R. E., Curson, D. A., et al (1997) One-year, low-dose neuroleptic study of inpatients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol. British Journal of Psychiatry, 171, 564-568.
82. Stanton, J. M. (1995) Weight gain associated with neuroleptic medication: A review Schizophrenia Bulletin, 21, 463-472.
83. Tamminga, C. A., Mack, R. J., Grannerman, G. R., et al (1997) Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety. International Clinical Psychopharmacology, 12 (suppl.), 29-35.
84. Thomas, S. H. L. (1994) Drugs, QT interval abnormalities and ventricular arrhythmias. Adverse Drug Reactions & loxicological Reviews, 13, 77-102.
85. Tollefson, G. D., Tran, P. V., Hamilton, S., et al (1997) Qtanzapine versus risperidone in the treatment of psychosis: Preliminary report (abstract). Schizophrenia Research, 24, 191-192.
86. _ , Beasley, C. M., Tamura, R. N., et al (1997b) Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. American Journal of Psychiatry, 154, 1248-1254.
87. Umbricht, D. & Kane, J. M. (1996a) Understanding the relationship between extrapyramidal side effects and tardive dyskinesia. In Serotonergic Mechanisms in Antipsychotic Treatment (eds J. M. Kane, H-J. Moller & E. Awouters), pp. 221-251. New York: Marcel Dekker.
88. _ , & _ , (1996b) Medical complications of new antipsychotic drugs. Schizophrenia Bulletin, 22, 475-483.
89. Van Kammen, D. P., McEvoy, J. P., Targum, S. D., et al (1996) A randomized, controlled, dose-ranging trial of sertindole in schizophrenia. Psychopharmacology, 124, 168-175.
90. Van Putten, T. & May, P. R. A. (1978) Akinetic depression in schizophrenia. Archives of General Psychiatry, 35, 1101-1107.
91. Warner, J. P., Harvey, C. & Barnes, T. R. E. (1996) Clozapine and enuresis. International Clinical Psychopharmacology, 9, 207-209.
92. Wehnert, A., Hale, A., Kasper, S., et al (1997) EPOS: Increasing our understanding of the treatment of schizophrenia. International Journal of Psychiatry in Clinical Practice, 1, 197-202.
93. Wirshing, W. C., Phelan, C. K., Van Putten, T., et al (1990) Effects of clozapine on treatment-resistant akathisia and concomitant tardive dyskinesia. Journal of Clinical Psychopharmacology, 10, 371-373.
94. Zehender, M., Hohnloser, S. & Just, H. (1991) QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards. Cardiovascular Drugs and Therapy, 5, 515-530.